| Document |
Document Title |
|
JP4711391B2 |
This invention relates to novel 1,4- diazabicycloalkane derivatives of formula (I): any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, and their use in...
|
|
JP2011116663A |
To provide a benzodiazepine compound useful in producing a drug of a wider therapeutic spectrum, capable of exhibiting sufficient therapeutic effect in a short time.The benzodiazepine compound is represented by formula (1) [in the formul...
|
|
JP4699663B2 |
The invention concerns a benzodiazepin derivative of formula (I) and their use for treating dyslipidemia, atherosclerosis, diabetes and its complications.
|
|
JP2011111419A |
To provide a pharmaceutical drug that has a wider therapeutic spectrum and is capable of exerting sufficient therapeutic effect within a short period of time.The pharmaceutical drug comprises a benzodiazepine compound represented by form...
|
|
JP4694747B2 |
Compounds according to general formula (1), and pharmaceutically acceptable salts thereof, wherein V is a covalent bond or NH, X is selected from CH2, O and N-alkyl, Z is either S or -CH=CH-, R<1 >and R<2 >are independently selected from...
|
|
JP4691669B2 |
Disclosed herein is at least one cyclopropyl amide derivative of formula I, at least one pharmaceutical composition comprising at least one cyclopropyl amide derivative of formula I disclosed herein, and at least one method of using at l...
|
|
JP4681737B2 |
The present invention relates to novel pyrido-thieno-diazepines, their preparation process and the pharmaceutical compositions containing them. These diazepines are particularly useful for treating pathological states or diseases in whic...
|
|
JP4667862B2 |
Methods and compositions for treating disease caused by infectious agents, particularly tuberculosis. In particular, methods and compositions comprising substituted ethylene diamines for the treatment of infectious diseases are provided....
|
|
JP4662914B2 |
The invention relates to malonamide derivatives of formula wherein each of the variables are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The compounds are gamma-secretase inhibitors. Th...
|
|
JP2011042655A |
To provide a compound which effectively lowers the phosphorus concentration in blood serum and hence can effectively prevent or cure diseases caused by an increase in the phosphorus concentration in blood serum.The compound is represente...
|
|
JP4644655B2 |
Pharmaceutically active diazepanes, e.g. useful for treating disorders or diseases mediated by LFA-1/ICAM-1, LFA-1/ICAM-2, LFA-1/ICAM-3 or LFA-1/JAM-1 interactions.
|
|
JP2011504909A |
This invention relates to novel carboxylic acid 4-phenylazo-phenyl ester derivatives useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy ...
|
|
JP4634694B2 |
The invention provides conjugates of fatty alcohols and pharmaceutical agents useful in treating cancer, viruses, psychiatric disorders. Compositions, pharmaceutical preparations, and methods of preparation of the fatty alcohols-pharmace...
|
|
JP4630665B2 |
The present invention relates to compounds, related to 2,3 benzodiazepines, of general formula (I), such as Tofisopam, Girisopam or Nerisopam, for use in the treatment of dyskinesia. The dyskinesia may arise as a side-effect of a therapy...
|
|
JP2011016801A |
To provide a new arylsulfonamide compound for prevention and treatment of obesity, type II diabetes and central nervous system diseases.There is provided a substituted bis-arylsulfonamide compound expressed by formula (II) or its pharmac...
|
|
JP4619545B2 |
The invention concerns amide derivatives of Formula (Ia) wherein X is -NHCO- or -CONH-; m is 0-3; R1 is a group such as hydroxy, halogeno, trifluoromethyl, cyano, mercapto, nitro, amino, carboxy and carbamoyl; n is 0-2; R2 is a group suc...
|
|
JP4615727B2 |
This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit t...
|
|
JP4611308B2 |
The present invention relates to methods of treatment for symptoms of gastrointestinal dysfunction and related stress that are frequently associated with, for example, irritable bowel syndrome. The symptoms include altered bowel motility...
|
|
JP4611030B2 |
Compounds according to formula I:wherein R<1>, R<2>, R<3>, R<4>, R<5 >and n are as defined herein, are administered for the treatment of inflammatory disorders mediated by LTB4.
|
|
JP2011001296A |
To find out a compound which promotes insulin secretion from a pancreas β-cell and to provide a preventing and/or therapeutic agent for a disease resulting from hyperglycemia, for example diabetes.The insulin secretion promoter makes N,...
|
|
JP2011500820A |
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are ...
|
|
JP4607809B2 |
Piperazine derivatives (I) and their optical isomers, and acid addition salts are new. Piperazine derivatives of formula (I) and their optical isomers, and acid addition salts are new. R 1-R 4H, halo, 1-6C alkyl, 1-6C alkoxy, phenyl or C...
|
|
JP2010285442A |
To provide a vasopressin V1a receptor antagonist useful as a therapeutic agent for such as dysmenorrhea (primary dysmenorrhea and/or secondary dysmenorrhea), early labor pain, hypertension, Raynaud's disease, cerebral edema, motion sickn...
|
|
JP4597480B2 |
The present invention relates to substituted bis-arylsulfonamide and arylsulfonamide compounds of the general formula (I) or the formula (II), which compounds are potentially useful for the prophylaxis and treatment of medical conditions...
|
|
JP2010536769A |
In its many embodiments, the present invention relates to a novel class of substituted azepine- and diazepine-sulfonamide compounds useful to inhibit 11β-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the co...
|
|
JP4572433B2 |
|
|
JP4568113B2 |
The invention relates to substituted diaryl heterocycles and the physiologically compatible salts and physiologically functional derivates thereof. The invention also relates to compounds of formula (I), wherein the radicals have the abo...
|
|
JP4571639B2 |
The invention relates to malonamide derivatives of formula wherein each of the variables are as defined herein and to pharmaceutically acceptable acid addition salts, optically pure enantiomers, racemates and diastereomeric mixtures ther...
|
|
JP4570773B2 |
Heteroaryl diazacycloalkane derivatives (I) are new. Heteroaryl diazacycloalkane derivatives of formula (I) and their enantiomers or mixtures, isotopes and salts are new. [Image] n : 1-3 m : 0-2; R : H, alkyl, cycloalkyl, cycloalkylalkyl...
|
|
JP2010229153A |
To provide compounds blocking activity of γ-secretase able to be used for treating Alzheimer's disease.Malonamide derivatives expressed by formula (I) [in formula (I), R1 represents a group expressed by formula (a)], pharmaceutically su...
|
|
JP4557112B2 |
A compound represented by the following general formula (1) : wherein R<1> represents a halogen atom, R<2> represents hydrogen atom or a lower alkyl group, and R<3> represents hydrogen atom, a lower alkyl group, a lower alkoxyl group, a ...
|
|
JP4551988B2 |
The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates the...
|
|
JP4549452B2 |
|
|
JP2010530736A |
Methods for screening for inhibitors of endoplasmic reticulum (ER) stress are provided. These methods involve the addition of thapsigargin, which induces ER stress, and a test agent to mammalian cells in multi-well plates. Cell survival ...
|
|
JP4522651B2 |
Disclosed are novel compounds of the formula Also disclosed are pharmaceutical compositions comprising the compounds of Formula I. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, alle...
|
|
JP2010526825A |
The aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepine derivative compounds of the present invention are represented by formulae 1(A-D) having the following structure: where the substituents X and R1-R8 are as defined herein.
|
|
JP4516765B2 |
|
|
JP4517047B2 |
The present invention relates to a sulfonamide derivative which is useful as an active ingredient of pharmaceutical preparations. The sulfonamide derivatives of the present invention have CCR3 (CC type chemokine receptor) antagonistic ac...
|
|
JP2010520883T5 |
|
|
JP2010524879A |
The present invention relates to compounds of formula (I), a process for the manufacture thereof, their use for the preparation of medicaments for treating CNS disorders and pharmaceutical compositions containing them. Compounds of formu...
|
|
JPWO2008133155A1 |
To provide a drug having a P2Y12 inhibitory action, particularly a compound useful as a platelet aggregation inhibitor. As a result of diligent studies on P2Y12 inhibitors, the inventors have quinazoline dione, isoquinolone characterized...
|
|
JP4509551B2 |
Benzo or heterocyclo fused aza-bicycloalkane derivatives (I) are new. Also new are seven classes of intermediates. Benzo or heterocyclo fused aza-bicycloalkane derivatives of formula (I) and their salts with acids or bases are new. [Imag...
|
|
JP4505753B2 |
An agent for increasing the sugar-transporting capacity and an agent for preventing and/or treating diabetes, diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic macroangiopathy, impaired glucose toleranc...
|
|
JP4499917B2 |
The present invention relates to novel classes of compounds which are caspase inhibitors, in particular interleukin-1beta converting enzyme ("ICE") inhibitors. This invention also relates to pharmaceutical compositions comprising these c...
|
|
JP4502509B2 |
The invention concerns amide derivatives of the Formula (I)wherein R<3 >is (1-6C)alkyl or halogeno; Q is aryl or heteroaryl which optionally bears 1, 2, 3 or 4 substituents such as hydroxy, halogeno, trifluoromethyl, cyano, (1-6C)alkyl, ...
|
|
JP4503607B2 |
The present invention provides compounds of the general formula wherein R4 is one of the following groups and R1, R2, R3, R7, R8, and R9 are as defined in the specification and pharmaceutically acceptable salts, optically pure enantiomer...
|
|
JP4500689B2 |
The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double...
|
|
JP4503826B2 |
The invention provides a pharmaceutically acceptable oleaginous or cholesterol microsphere formulation of olanzapine or olanzapine pamoate or solvates thereof. The invention further provides novel olanzapine pamoate salts or solvates the...
|
|
JP4497921B2 |
The present invention is directed to novel 1,4-benzodiazepines, pharmaceutical compositions thereof, and the use thereof as inhibitors of HDM2-p53 interactions. Compounds have Formula I: or a solvate, hydrate or pharmaceutically acceptab...
|
|
JP4491072B2 |
Benzodiazepine compounds (I) of formula (I'; R = H), and their salts, are new: R1 = 1-4C alkyl, 2-4C alkenyl, 2-4C alkynyl, 3-4C oxoalkenyl, 3-4C oxoalkynyl, 1-4C aminoalkyl, 3-4C aminoalkenyl, 3-4C aminoalkynyl, (all optionally substitu...
|
